J
John G.F. Cleland
Researcher at National Institutes of Health
Publications - 1276
Citations - 125527
John G.F. Cleland is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Heart failure & Ejection fraction. The author has an hindex of 137, co-authored 1172 publications receiving 110227 citations. Previous affiliations of John G.F. Cleland include Northwestern University & Imperial College London.
Papers
More filters
Journal ArticleDOI
Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure
Dipak Kotecha,Dipak Kotecha,Simrat Gill,Marcus Flather,Jane Holmes,Milton Packer,Giuseppe M.C. Rosano,Michael Böhm,John J.V. McMurray,John Wikstrand,Stefan D. Anker,Dirk J. van Veldhuisen,Luis Manzano,Thomas G. von Lueder,Thomas G. von Lueder,Alan S. Rigby,Bert Andersson,John Kjekshus,Hans Wedel,Frank Ruschitzka,John G.F. Cleland,Kevin Damman,Josep Redon,Andrew J.S. Coats +23 more
TL;DR: Patients with heart failure, left ventricular ejection fraction <50% and sinus rhythm should receive beta-blocker therapy even with moderate or moderately severe renal dysfunction, according to renal function using estimated glomerular filtration rate (eGFR).
Journal Article
Left Ventricular Ejection Fraction and Volumes from Gated Blood-Pool SPECT: Comparison with Planar Gated Blood-Pool Imaging and Assessment of Repeatability in Patients with Heart Failure
TL;DR: GBPS provides a less repeatable measurement of LVEF than PRNV, and repeatability of LVEDV measurements from GBPS is poor.
Journal ArticleDOI
Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel.
Mitchell A. Psotka,William T. Abraham,Mona Fiuzat,Gerasimos Filippatos,JoAnn Lindenfeld,Tariq Ahmad,Ankeet S. Bhatt,Peter E. Carson,John G.F. Cleland,G. Michael Felker,James L. Januzzi,Dalane W. Kitzman,Eric S. Leifer,Eldrin F. Lewis,John J.V. McMurray,Robert J. Mentz,Scott D. Solomon,Norman Stockbridge,John R. Teerlink,Muthiah Vaduganathan,Orly Vardeny,David J. Whellan,Janet Wittes,Stefan D. Anker,Christopher M. O'Connor +24 more
TL;DR: A series of meetings were convened to address the challenges caused by the COVID-19 pandemic, review options for maintaining or altering best practices, and establish key recommendations for the conduct and analysis of clinical trials for cardiovascular disease and heart failure.
Journal Article
Health economic consequences of the pharmacological treatment of heart failure.
TL;DR: This article seeks to review currently available reports on the health economic consequences of interventions for heart failure and describes the development of a new health economic model that appears to be cost-effective under widely differing sets of assumptions.
Journal ArticleDOI
Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure.
Jozine M. ter Maaten,Mattia A.E. Valente,Kevin Damman,John G.F. Cleland,John G.F. Cleland,Michael M. Givertz,Michael M. Givertz,Marco Metra,Marco Metra,Christopher M. O'Connor,John R. Teerlink,John R. Teerlink,Piotr Ponikowski,Piotr Ponikowski,Daniel M. Bloomfield,Daniel M. Bloomfield,Gadi Cotter,Beth A. Davison,Haris Subacius,Haris Subacius,Haris Subacius,Dirk J. van Veldhuisen,Peter van der Meer,Hans L. Hillege,Mihai Gheorghiade,Mihai Gheorghiade,Mihai Gheorghiade,Adriaan A. Voors +27 more
TL;DR: Combining 2 indicators of decongestion, hemoconcentration and diuretic response improves risk prediction for early rehospitalization after an admission for acute HF and may provide clinicians with an easily accessible tool to identify low-risk patients.